Denver, United States
AOA Dx is at the forefront of innovation in the realm of early-stage cancer detection, setting new precedents in Biotechnology and Health Care. Established in 2020, the company is based in the United States and is committed to transforming women’s health via breakthrough diagnostics.
The core of AOA Dx's innovation lies within its proprietary GlycoLocate platform. This multi-omics approach leverages a blend of lipids, metabolites, and proteins to achieve superior early cancer diagnostics. The platform’s flagship, AKRIVIS GD™, is a liquid biopsy test designed for early ovarian cancer detection, potentially redefining the standard for life-saving diagnostics.
Having recently secured an Early VC investment as of 01 October 2025, AOA Dx is poised for further growth and scalability. With AI at its helm, the company exemplifies a promising investment opportunity in a rapidly evolving sector.
